Tibotec and FDA Update Warnings for Intelence

Tibotec and FDA Update Warnings for Intelence
August 27, 2009
Audience: Infectious disease healthcare professionals, patients.

Tibotec Therapeutics and FDA notified healthcare professionals of
revisions to the WARNINGS AND PRECAUTIONS section of the prescribing
information for Intelence (etravirine). There have been postmarketing
reports of cases of Stevens-Johnson syndrome, toxic epidermal
necrolysis and erythema multiforme, as well as hypersensitivity
reactions characterized by rash, constitutional findings, and
sometimes organ dysfunction, including hepatic